Sprechstunde

über alles was uns krank macht

Posts Tagged ‘Massenimpfungen

Lieferschwierigkeiten beim Impfstoff, wer hätte das gedacht ?!?!

leave a comment »


Wie hier zuletzt unter Zum Unterschied zwischen SarsCov2 Vakzin und Mon Chéri schon gesagt, gehört es zu den Todsünden im Marketing einen Bedarf (z.B. durch Showimpfungen) anzufeuern, dem dann das Angebot nicht entsprechen kann.
Genau das hat unsere tückisch-grüne Regierung gehörig versemmelt, aber wer hätte das den wissen können, dass Pfizer Biontech in Lieferrückstand kommen werden?

Klar setzt man sich mit einer solchen Frage der Besserwisserei im Nachhinein aus, nur hätte unsere Politik mehr auf Fachleute gehört als auf ihre PR Berater, wäre auch ihnen schon lange klar, dass die Probleme in der Bugwelle der Operation Warp Speed lauern. Ein kurzer Überblick, dass die Probleme der Massenproduktion und Distribution dieser Impfstoffe schon lange vielen klar war.

ARUP im Mai 2020: Producing the cure: how can the pharmaceutical industry meet global demand for a COVID-19 vaccine? Questions of supply chain management are always about how many elements interlock, and this challenge is no different. To succeed, and stay successful, producers will need to examine every upstream and downstream factor in the vaccine’s supply chain, from raw materials to energy supply to packaging, storage, security and fulfilment. It’s a case of designing in the resilience now, by exploring these factors and assessing risk.

Bloomberg schrieb im Juli 2020: The World’s Supply Chain Isn’t Ready for a Covid-19 Vaccine

PWC hat im September 2020 geschrieben: COVID-19 vaccines are being developed at a breakneck pace, but a broken supply chain could derail that momentum

Aircargo News im September 2020: This week, several logistics parties have cited that not only the development of the vaccine is a feat, but that rolling out the logistics chain for the distribution of a Covid-19 vaccine will be particularly challenging. IATA, the international airline federation, said this week that the transportation of the Covid-19 vaccines would require more than 8,000 747 jumbo freighters.

The last mile distribution: the potential quality killer …

ABC News November 2020: But with limited supplies of each vaccine available at first, enough to vaccinate only 20 million Americans by the end of the year, experts agree the U.S. needs multiple vaccines to fight the pandemic. That includes not only Pfizer and Moderna’s vaccine but also even more that are further behind in development.

Bruce Y. Lee, der seit 15 Jahren das Public Health Informatics, Computational, Operations Research (PHICOR) team leitet warnte im noch im Dezember 2020: The success of vaccines against it depends not only on the characteristics of vaccines but whether they are actually delivered to everyone. As history has shown, vaccine supply chains are far more complex than many people realize.

Global News 3. Dezember 2020: Pfizer had adjusted its supply outlook in 2020 from 100 million to 50 million in November in publicly available statements, but had promised up to 100 million doses as late as September.

Scientific American (!) 4. 1.2021: New COVID Vaccines Need Absurd Amounts of Material and Labor
Pfizer and Moderna have been building supply networks to shift from clinical to large-scale production. But each step in the manufacturing process requires raw materials that, before COVID, were only produced in the amounts needed for clinical research—“not sustained production of billions of doses.

NPR 17. Dezember 2020: Pfizer makes hundreds of medicines and vaccines and operates at least 40 manufacturing facilities registered with the FDA around the world. Despite being founded a decade ago, Moderna has never had a product win FDA approval. And it only has one factory registered with the FDA — and the registration occurred just this week.

DW 11.1.2021:

More shots per vial and new factories
A dilution of the vaccine was approved by EU regulators on Friday, which means each vial can now be used for six shots instead of five.
BioNTech also said it has added a new manufacturing site in Marburg, Germany, which is set to go online in February and will boost annual production capacity by up to 750 million doses.
The vaccine is currently being produced at BioNTech’s headquarters in Mainz, Germany, a location in Belgium, and at several factories in the US.
50 million doses already made.

Naja, treue Leser dieses Blogs haben das natürlich auch schon früher gewusst:

30. Dezember 2020: Was in dem Gezwitscher um die Wirksamkeit von Impfungen untergeht: Der Herstellungsprozess
13. Dezember 2020: Wann und wie wird die SarsCov2 Pandemie enden?
9. Dezember 2020: Das Covid-19 Impf-Dilemma hat schon Hippokrates vorhergesehen (Update 6.1.2021)
1. Dezember 2020: Regelmäßig aktualisierter Überblick über mögliche Impfungen gegen das Coronavirus

27. November 2020: Aus dem Lockdown in die Gondel: das Kleingedruckte, das der Bundesmaturant verschweigt
27. November: Einer der interessantesten Artikel über die Geschichte der mRNA Impfstoffe, die ich bis jetzt gelesen habe

Written by medicus58

19. Januar 2021 at 17:52

%d Bloggern gefällt das: